

University of Groningen

EPAC-Lung

Lindsay, C R; Blackhall, F H; Carmel, A; Gazzaniga, P; Groen, H J M; Krebs, M G; Muinelo-Romay, L; Pantel, K; Rossi, E; Terstappen, L

Published in:
Annals of Oncology

DOI:
[10.1093/annonc/mdz073](https://doi.org/10.1093/annonc/mdz073)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Lindsay, C. R., Blackhall, F. H., Carmel, A., Gazzaniga, P., Groen, H. J. M., Krebs, M. G., Muinelo-Romay, L., Pantel, K., Rossi, E., Terstappen, L., Wikman, H., Soria, J.-C., Farace, F. F., Renehan, A., Dive, C., Besse, B., & Michiels, S. (2019). EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer. *Annals of Oncology*, 30 (Suppl 2), ii7. <https://doi.org/10.1093/annonc/mdz073>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

TRANSLATIONAL RESEARCH

210 EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer

C.R. Lindsay¹, F.H. Blackhall², A. Carmel³, P. Gazzaniga⁴, H.J.M. Groen⁵, M.G. Krebs⁶, L. Muinelo-Romay⁷, K. Pantel⁸, E. Rossi⁹, L. Terstappen¹⁰, H. Wikman⁸, J-C. Soria¹¹, F.F. Farace³, A. Renehan¹, C. Dive¹², B. Besse¹³, S. Michiels¹⁴

¹The Christie NHS Foundation Trust, Manchester, UK, ²Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK, ³Institut Gustave Roussy, Villejuif, France, ⁴Policlinico Umberto I - Unità di Neonatologia, Patologia e Terapia Intensiva Neonatale, Rome, Italy, ⁵University Hospital Groningen (UMCG), Groningen, Netherlands, ⁶Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, ⁷Health Research Institute of Santiago de Compostela (IDIS), CIBERONC, Santiago De Compostela, Spain, ⁸UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany, ⁹Istituto Oncologico Veneto IRCCS, Padua, Italy, ¹⁰Medical Cell Biophysics, Enschede, Netherlands, ¹¹Medimmune, Gaithersburg, MD, USA, ¹²Clinical & Experimental Pharmacology, Cancer Research UK Manchester Institute, Manchester, UK, ¹³Department of Cancer Medicine, Gustave Roussy - Cancer Campus, Villejuif, France, ¹⁴Team Oncostat, CESP, Gustave Roussy, Villejuif, France

Background: We assessed the clinical validity of circulating tumor cell (CTC) quantification for prognostication of patients with advanced non-small cell lung cancer (NSCLC) by undertaking a European pooled analysis of individual patient data. This is the largest study of its kind and the first to examine between-centre heterogeneity of CTC identification in NSCLC.

Methods: Nine European NSCLC CTC centers were asked to provide reported/unreported anonymised data for patients with advanced NSCLC who participated in CellSearch CTC studies from January 2003 - March 2017. We used Cox regression models, stratified by centre, to establish the association between CTC count and survival. We assessed the added value of CTCs to prognostic clinico-pathological models using likelihood ratio (LR) statistics and c-indices.

Results: Seven out of nine eligible centers provided data for 550 eligible patients, including 209 patients whose prognostic information was previously unpublished. CTC counts of ≥ 2 and ≥ 5 per 7.5 mL were associated with reduced progression-free survival (≥ 2 CTCs: HR 1.72, $p < 0.001$; ≥ 5 CTCs: HR 2.21, $p < 0.001$) and overall survival (≥ 2 CTCs: HR 2.18, $p < 0.001$; ≥ 5 CTCs: HR 2.75, $p < 0.001$), respectively. Survival prediction was significantly improved by addition of baseline CTC count to LR clinico-pathological models (log-transformed CTCs $p < 0.0001$; ≥ 2 CTCs $p < 0.0001$; ≥ 5 CTCs $p < 0.0001$), while more moderate improvements were observed with the use of c-index models. There was minor evidence of between-center heterogeneity in the effect on PFS, but not OS. No difference in CTC profile was observed between key NSCLC molecular subsets such as EGFR, ALK, and KRAS.

Conclusions: These data confirm CTCs as an independent prognostic indicator of progression-free survival and overall survival in advanced NSCLC. CTC count improves prognostication when added to full clinico-pathological predictive models. ≥ 2 CTCs is an appropriate cutoff to move towards establishing clinical utility.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding.

Disclosure: C.R. Lindsay: Institutional funding for an ongoing phase II trial for which I am PI; Supported by Roche as part of an ESMO translational fellowship awarded in 2014-2016. F.H. Blackhall: Grants: AstraZeneca, Novartis, Pfizer, Amgen, BMS; Consultancy fees: Cell Medica, MSD; Speaker bureau: BI; Advisory board work: Regeneron, Medivation, AbbVie, Takeda, Roche, Ipsen. M.G. Krebs: Advisory board: J&J. L. Terstappen: Inventor on a number of US patents related to CellSearch, rights of which assigned to Johnson&Johnson, CellSearch kits obtained from Johnson&Johnson through a collaborative agreement with the MCBP. J-C. Soria: Consultancy fees: AZ, Astex, Clovis, GSK, GamaMabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche/Genentech, Sanofi, Servier, Symphogen, Takeda; Full time employee: MedImmune; Shareholder: AZ, Gritstone. All other authors have declared no conflicts of interest.